CLN.WA
Celon Pharma S.A. [CLN.WA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CLN.WA Stock Summary
Top 10 Correlated ETFs
CLN.WA
Top 10 Correlated Stocks
CLN.WA
In the News
CLN.WA Financial details
Company Rating
Neutral
Market Cap
765.85M
Income
-19.13M
Revenue
167.89M
Book val./share
9.01
Cash/share
2
Dividend
0.09
Dividend %
0.57%
Employees
513
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
-43.29
Forward P/E
-
PEG
-9.02
P/S
4.8
P/B
1.8
P/C
7.39
P/FCF
-26.11
Quick Ratio
1.44
Current Ratio
1.74
Debt / Equity
0.04
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.37
EPS next Y
-
EPS next Q
-
EPS this Y
208%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
5.27%
Revenue Q/Q
0.64%
EPS Q/Q
-172.22%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-3%
ROE
-4%
ROC
-0.03%
Gross Margin
60%
Oper. Margin
-9%
Profit Margin
-11%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13.1-17.94
52W High
-13.06%
52W Low
+13.69%
RSI
44
Rel Volume
1.11
Avg Volume
14.34K
Volume
15.97K
Perf Week
-1.99%
Perf Month
-1.99%
Perf Quarter
-2.38%
Perf Half Y
-3.27%
-
-
-
-
Beta
0.799
-
-
Volatility
0.1%, 0.25%
Prev Close
-1.47%
Price
14.78
Change
-0.27%
CLN.WA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.78 | 2.27 | 3.09 | 3.63 | 3.17 | |
| Net income per share | 0.66 | 0.27 | 0.48 | -0.25 | -0.77 | |
| Operating cash flow per share | 0.63 | -0.11 | 1.58 | 0.94 | -0.09 | |
| Free cash flow per share | -0.87 | -1.56 | -0.63 | 0.06 | -0.76 | |
| Cash per share | 4.5 | 1.48 | 0.98 | 4.88 | 3.23 | |
| Book value per share | 9.97 | 9.89 | 9.66 | 11.87 | 9.4 | |
| Tangible book value per share | 9.81 | 9.75 | 8.75 | 11.24 | 8.95 | |
| Share holders equity per share | 9.97 | 9.89 | 9.66 | 11.87 | 9.4 | |
| Interest debt per share | 0.05 | 0.04 | 0.53 | 0.35 | 0.56 | |
| Market cap | 1.41B | 1.79B | 1.82B | 1.55B | 715.36M | |
| Enterprise value | 1.26B | 1.72B | 1.8B | 1.41B | 659.28M | |
| P/E ratio | 47.35 | 149.69 | 84.89 | -133.31 | -18.21 | |
| Price to sales ratio | 11.23 | 17.47 | 13.1 | 9.13 | 4.42 | |
| POCF ratio | 49.8 | -353.71 | 25.74 | 35.21 | -152.17 | |
| PFCF ratio | -35.86 | -25.52 | -64.57 | 595.13 | -18.53 | |
| P/B Ratio | 3.13 | 4.01 | 4.2 | 2.79 | 1.49 | |
| PTB ratio | 3.13 | 4.01 | 4.2 | 2.79 | 1.49 | |
| EV to sales | 10.05 | 16.84 | 12.95 | 8.34 | 4.07 | |
| Enterprise value over EBITDA | 22.66 | 61.62 | 26.64 | 51.11 | 70.44 | |
| EV to operating cash flow | 44.59 | -340.84 | 25.44 | 32.18 | -140.24 | |
| EV to free cash flow | -32.11 | -24.59 | -63.83 | 544.02 | -17.08 | |
| Earnings yield | 0.02 | 0.01 | 0.01 | -0.01 | -0.05 | |
| Free cash flow yield | -0.03 | -0.04 | -0.02 | 0 | -0.05 | |
| Debt to equity | 0 | 0 | 0.05 | 0.03 | 0.06 | |
| Debt to assets | 0 | 0 | 0.03 | 0.02 | 0.04 | |
| Net debt to EBITDA | -2.65 | -2.33 | -0.31 | -4.8 | -5.99 | |
| Current ratio | 10.84 | 5.53 | 1.69 | 3.23 | 2.04 | |
| Interest coverage | 31.09 | 37.16 | 65.63 | -8.8 | -20.79 | |
| Income quality | 0.95 | -0.42 | 3.3 | -2.91 | 0.13 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0.02 | |
| Payout ratio | 0.26 | 0.6 | 0.17 | -0.27 | -0.38 | |
| Sales general and administrative to revenue | 0.15 | 0.16 | 0.08 | 0.22 | 0 | |
| Research and developement to revenue | 0 | 0 | 0.3 | 0.29 | 0.39 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.06 | 0.04 | 0.04 | |
| Capex to operating cash flow | -2.39 | 12.86 | -1.4 | -0.94 | 7.21 | |
| Capex to revenue | -0.54 | -0.64 | -0.71 | -0.24 | -0.21 | |
| Capex to depreciation | -3.92 | -3.15 | -3.21 | -1 | -0.77 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 12.17 | 7.68 | 10.19 | 8.15 | 12.76 | |
| ROIC | 0.06 | 0.02 | 0.08 | -0.02 | -0.07 | |
| Return on tangible assets | 0.05 | 0.02 | 0.03 | -0.02 | -0.07 | |
| Graham Net | 2.21 | -0.67 | -3.99 | 2.28 | 1.56 | |
| Working capital | 194.03M | 117.59M | 48.35M | 192.34M | 121.14M | |
| Tangible asset value | 441.32M | 438.88M | 393.58M | 524.83M | 456.85M | |
| Net current asset value | 98.81M | -2.73M | -150.05M | 125.57M | 108.29M | |
| Invested capital | 0 | 0 | 0.05 | 0.03 | 0.06 | |
| Average receivables | 0.5 | 22.89M | 43.9M | 34.63M | 30.47M | |
| Average payables | 7.47M | 8.18M | 12.73M | 15.39M | 15.49M | |
| Average inventory | 20.83M | 26.83M | 28.94M | 25.59M | 30.88M | |
| Days sales outstanding | 0 | 163.42 | 110.13 | 58.65 | 75.97 | |
| Days payables outstanding | 116.64 | 115.08 | 206.29 | 75 | 100.53 | |
| Days of inventory on hand | 305.8 | 469.81 | 317.13 | 138.23 | 210.81 | |
| Receivables turnover | 125.24M | 2.23 | 3.31 | 6.22 | 4.8 | |
| Payables turnover | 3.13 | 3.17 | 1.77 | 4.87 | 3.63 | |
| Inventory turnover | 1.19 | 0.78 | 1.15 | 2.64 | 1.73 | |
| ROE | 0.07 | 0.03 | 0.05 | -0.02 | -0.08 | |
| Capex per share | -1.5 | -1.44 | -2.2 | -0.89 | -0.66 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.77 | 0.87 | 0.76 | 0.83 | 0.83 | |
| Net income per share | -0.23 | -0.23 | -0.19 | 0.18 | -0.13 | |
| Operating cash flow per share | -0.29 | 0.44 | -0.32 | -0.15 | 0.16 | |
| Free cash flow per share | -0.4 | 0.22 | -0.48 | -0.38 | 0.04 | |
| Cash per share | 3.12 | 3.23 | 2.63 | 2.19 | 2 | |
| Book value per share | 9.69 | 9.4 | 9.18 | 9.14 | 9.01 | |
| Tangible book value per share | 9.21 | 8.95 | 8.79 | 8.79 | 8.69 | |
| Share holders equity per share | 9.69 | 9.4 | 9.18 | 9.14 | 9.01 | |
| Interest debt per share | 0.41 | 0.54 | 0.55 | 0.44 | 0.34 | |
| Market cap | 659.55M | 715.51M | 765.53M | 791.38M | 781.16M | |
| Enterprise value | 602.05M | 659.43M | 742.79M | 788.12M | 775.86M | |
| P/E ratio | -14.13 | -14.93 | -20.2 | 21.64 | -28.66 | |
| Price to sales ratio | 16.91 | 16.2 | 19.63 | 18.74 | 18.38 | |
| POCF ratio | -45.26 | 31.81 | -47.33 | -103.31 | 96.34 | |
| PFCF ratio | -32.86 | 64.76 | -31.07 | -40.74 | 369 | |
| P/B Ratio | 1.34 | 1.49 | 1.63 | 1.7 | 1.7 | |
| PTB ratio | 1.34 | 1.49 | 1.63 | 1.7 | 1.7 | |
| EV to sales | 15.44 | 14.93 | 19.04 | 18.66 | 18.26 | |
| Enterprise value over EBITDA | 919.16 | 114.72 | -387.88 | 32.92 | 315.52 | |
| EV to operating cash flow | -41.32 | 29.32 | -45.93 | -102.89 | 95.69 | |
| EV to free cash flow | -29.99 | 59.69 | -30.15 | -40.57 | 366.49 | |
| Earnings yield | -0.02 | -0.02 | -0.01 | 0.01 | -0.01 | |
| Free cash flow yield | -0.03 | 0.02 | -0.03 | -0.02 | 0 | |
| Debt to equity | 0.04 | 0.06 | 0.06 | 0.05 | 0.04 | |
| Debt to assets | 0.03 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Net debt to EBITDA | -87.79 | -9.76 | 11.87 | -0.14 | -2.16 | |
| Current ratio | 2.67 | 2.04 | 2.05 | 2.33 | 1.74 | |
| Interest coverage | -19.77 | -5.98 | -18.02 | 16.67 | -16.17 | |
| Income quality | 1.28 | -4.64 | 1.4 | -1.08 | -1 | |
| Dividend Yield | 0.02 | 0 | 0 | 0 | 0 | |
| Payout ratio | -1.27 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 1.41 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0.38 | -0.51 | 0.52 | 1.54 | -0.74 | |
| Capex to revenue | -0.14 | -0.26 | -0.22 | -0.28 | -0.14 | |
| Capex to depreciation | -0.47 | -1.24 | -0.72 | -0.93 | -0.47 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | 0 | 0 | |
| Graham number | 7.08 | 7.05 | 6.19 | 6.07 | 5.2 | |
| ROIC | -0.02 | -0.02 | -0.02 | 0.02 | -0.02 | |
| Return on tangible assets | -0.02 | -0.02 | -0.02 | 0.02 | -0.01 | |
| Graham Net | 1.1 | 1.56 | 0.57 | 0.68 | 0.69 | |
| Working capital | 146.43M | 121.14M | 106.98M | 107.27M | 75.87M | |
| Tangible asset value | 467.14M | 456.85M | 448.38M | 448.74M | 443.58M | |
| Net current asset value | 84.95M | 108.29M | 59.47M | 63.36M | 62.91M | |
| Invested capital | 0.04 | 0.06 | 0.06 | 0.05 | 0.04 | |
| Average receivables | 37.19M | 36.28M | 33.91M | 38.68M | 43.95M | |
| Average payables | 23.91M | 24.91M | 19.1M | 16.78M | 15.71M | |
| Average inventory | 32.85M | 36.78M | 38.35M | 34.17M | 29.92M | |
| Days sales outstanding | 89.69 | 68.69 | 78.71 | 92.19 | 94.53 | |
| Days payables outstanding | 186.32 | 88.16 | 109.85 | 76.08 | 97.87 | |
| Days of inventory on hand | 208.02 | 184.86 | 211.48 | 167.2 | 164.29 | |
| Receivables turnover | 1 | 1.31 | 1.14 | 0.98 | 0.95 | |
| Payables turnover | 0.48 | 1.02 | 0.82 | 1.18 | 0.92 | |
| Inventory turnover | 0.43 | 0.49 | 0.43 | 0.54 | 0.55 | |
| ROE | -0.02 | -0.02 | -0.02 | 0.02 | -0.01 | |
| Capex per share | -0.11 | -0.22 | -0.17 | -0.23 | -0.12 |
CLN.WA Frequently Asked Questions
What is Celon Pharma S.A. stock symbol ?
Celon Pharma S.A. is a PL stock and trading under the symbol CLN.WA
What is Celon Pharma S.A. stock quote today ?
Celon Pharma S.A. stock price is $14.78 today.
Is Celon Pharma S.A. stock public?
Yes, Celon Pharma S.A. is a publicly traded company.
Company Profile
- Volume Average 14.34K
- Market Capitalization 765.85M
- Employee 513
- CEO Dr. Maciej Wieczorek Ph.D.
- Headquarters lomianki,PL
- IPO Date 2017-02-17
-
Website
https://www.celonpharma.com 
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.
